FDA Officials Emphasize Statutory Restrictions To Weighing Drug Costs

By Beth Wang
July 11, 2019 at 11:23 AM
SAN DIEGO -- FDA officials recently emphasized that drug pricing, while an important topic, is one that they generally can’t address as part of the regulatory process due to statutory restrictions. When asked about their thoughts on drug pricing issues during the DIA Annual Conference a couple of weeks ago, the agency officials emphasized they are limited in their ability to weigh cost, reimbursement and patient access. FDA representatives sitting on various panels throughout the week emphasized that drug...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.